Salarius Pharmaceuticals, Inc.
SLRX
$0.698
-$0.0348-4.75%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | -1.46M | -972.10K | -1.42M | -1.72M | -881.80K |
| Total Depreciation and Amortization | 1.10K | 1.10K | 1.10K | 1.10K | 1.10K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 51.00K | 60.00K | 85.20K | 77.50K | 85.40K |
| Change in Net Operating Assets | 669.30K | -445.70K | 266.00K | 282.70K | -715.90K |
| Cash from Operations | -742.50K | -1.36M | -1.07M | -1.35M | -1.51M |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | -- | -- | -- |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -107.00K | -69.90K | -116.90K | -172.80K | -169.40K |
| Issuance of Common Stock | 0.00 | 1.44M | 88.70K | 0.00 | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | 0.00 |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -107.00K | 1.37M | -28.20K | -172.80K | -169.40K |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -849.50K | 11.20K | -1.10M | -1.53M | -1.68M |